Silexion Therapeutics Ltd.
SLXN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $4 | $3 | $0 |
| G&A Expenses | $7 | $1 | $1 | $0 |
| SG&A Expenses | $7 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $5 | $4 | $1 |
| Operating Income | -$13 | -$5 | -$4 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$4 | -$0 | $0 | $0 |
| Pre-Tax Income | -$17 | -$5 | -$3 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$5 | -$3 | -$1 |
| % Margin | – | – | – | – |
| EPS | -2.64 | -4.42 | 0.035 | -0.046 |
| % Growth | 40.3% | -12,764.8% | 176.2% | – |
| EPS Diluted | -2.64 | -4.42 | 0.035 | -0.046 |
| Weighted Avg Shares Out | 6 | 1 | 17 | 17 |
| Weighted Avg Shares Out Dil | 6 | 1 | 17 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$5 | -$4 | -$1 |
| % Margin | – | – | – | – |